IMTX

Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Immatics N.V. (IMTX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D+). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.3
EV / EBITDA -3.1
Rev Growth YoY 33.5%
Gross Margin 0.0%
Price Return 3M -30.2%
Price Return 12M -25.9%
Catalyst Signal 0.00
Market Cap $1.0B
TTM Revenue $43.4M
Price / Sales 23.4
ROE -54.3%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B- (2.9) C (2.3) C (2.2) D+ (1.7) C+ (2.6) C (2.3)
2026-11-05 B- (2.9) C+ (2.6) C (2.2) D+ (1.8) C+ (2.7) C (2.4)
2026-10-29 B- (2.9) C+ (2.6) C (2.2) C- (2.0) C+ (2.7) C (2.5)
2026-10-22 B- (2.9) C+ (2.6) C (2.2) C- (2.0) C+ (2.6) C (2.4)
2026-10-15 B- (2.9) C+ (2.6) C (2.2) C- (1.9) C+ (2.6) C (2.4)
Page 1 of 4